2H0 Stock Chart & Stats
€1.25
-€0.03(-2.34%)
At close: 4:00 PM EDT
€1.25
-€0.03(-2.34%)
Day’s Range― - ―
52-Week Range€1.12 - €8.25
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€8.84M
Enterprise Value€24.54
Total Cash (Recent Filing)€2.60M
Total Debt (Recent Filing)€22.00K
Price to Earnings (P/E)―
Beta-1.91
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.54
Shares Outstanding6,373,937
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)8.69
Price to Sales (P/S)0.00
P/FCF Ratio-3.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetExicure’s elimination of total debt materially lowers near-term financial risk and interest burden, giving management more flexibility to allocate scarce capital to operations or R&D. A debt-free structure supports solvency and reduces fixed obligations over a multi-month horizon.
Board Refresh And GovernanceRecent board additions and a new compensation committee increase independent oversight and diversify skills on the board. Strengthened governance improves strategic discipline, decision quality, and investor confidence, which can support durable access to capital and better long-term execution.
Strategic Pivot To Hematologic FocusShifting from the original platform to a focused hematologic strategy creates clearer development priorities and target markets (e.g., multiple myeloma, sickle cell). Advancing a lead stem cell mobilization program provides a defined clinical path and a structural roadmap for near-term development milestones.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow indicates the company is consuming cash faster than it generates it, depleting reserves and forcing reliance on external financing. Over several months this raises dilution and execution risk if capital markets tighten or milestones slip.
No Meaningful RevenueA pre-revenue profile with recurring, sizable losses undermines self-funding capacity and makes long-term viability contingent on clinical success or new financing. Without durable revenue streams, operational continuity and R&D progression depend on external capital and create sustained dilution risk.
Eroding Equity CushionDeclining shareholders' equity and deeply negative ROE reflect ongoing capital erosion from losses, shrinking the company’s buffer to absorb future setbacks. A thinner equity base limits financing flexibility and heightens solvency risk if operating losses continue over the next several quarters.
Exicure News
2H0 FAQ
What was Exicure Inc’s price range in the past 12 months?
Exicure Inc lowest stock price was €1.12 and its highest was €8.25 in the past 12 months.
What is Exicure Inc’s market cap?
Exicure Inc’s market cap is €8.84M.
When is Exicure Inc’s upcoming earnings report date?
Exicure Inc’s upcoming earnings report date is Aug 07, 2026 which is in 4 days.
How were Exicure Inc’s earnings last quarter?
Exicure Inc released its earnings results on May 13, 2026. The company reported -€0.249 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Exicure Inc overvalued?
According to Wall Street analysts Exicure Inc’s price is currently Overvalued.
Does Exicure Inc pay dividends?
Exicure Inc does not currently pay dividends.
What is Exicure Inc’s EPS estimate?
Exicure Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Exicure Inc have?
Exicure Inc has 6,373,937 shares outstanding.
What happened to Exicure Inc’s price movement after its last earnings report?
Exicure Inc reported an EPS of -€0.249 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -5.344%.
Which hedge fund is a major shareholder of Exicure Inc?
Currently, no hedge funds are holding shares in DE:2H0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Exicure Inc
Exicure, Inc. is a biotechnology firm that utilizes its unique spherical nucleic acid (SNA) platform to create therapies for neurological conditions and hair loss. Its primary experimental candidate, SCN9A, is currently undergoing preclinical evaluation for addressing neuropathic and chronic pain. The company has entered into a strategic partnership with AbbVie Inc. to advance SNA-based solutions for various hair loss conditions, under a collaboration, option, and license agreement. Additionally, a separate collaborative effort with Ipsen S.A. aims to investigate, develop, and commercialize novel spherical nucleic acids targeting Huntington's disease and Angelman syndrome. Established in 2011, Exicure's corporate base is located in Chicago, Illinois.